Hep C Trial Arm Added Due to Favorable PSI-7977 Data
Share
Follow Us
The Editors at Hepatitis Central
October 13, 2011
Due to continued positive results, Pharmasset’s Hepatitis C trial for PSI-7977 has been expanded to include monotherapy.
Pharmasset expands hepatitis C trial; shares rise
Mon Oct 10, 2011
(Reuters) – Pharmasset Inc (VRUS.O) said it will expand a mid-stage trial of its experimental hepatitis C drug with the further addition of two arms, sending its shares to a life-high.
Pharmasset’s PSI-7977, which belongs to a class of compounds called nucleotide analogues, will now be studied for 12 weeks as a single drug treatment, while the other arm will test the drug in combination with ribavirin.
In addition, a previously announced arm of the trial has been modified to an interferon-free 12-week regimen, the company said in a statement.
Continue reading this entire article:
http://www.reuters.com/article/2011/10/10/us-pharmassetinc-idUSTRE7993PD20111010
